menu
    • menu

    Company profile for City Therapeutics

    NEW Drugs in Dev: 1
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    City Therapeutics is a biopharmaceutical company pioneering the next generation of RNA interference (RNAi)-based medicines. Founded by leading experts in RNAi, the company focuses on engineering small interfering RNAs (siRNAs) to enhance their potency, specificity, and delivery across various therapeutic areas. Their mission is to unlock RNAi's transformative potential to address a wide range of diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    City TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    399 Binney St. Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.citytx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    City Therapeutics Builds Rnai Pipeline With $99.5M Series B
    City Therapeutics Builds Rnai Pipeline With $99.5M Series B

    08 Jun 2026

    // BIOSPACE

    https://www.biospace.com/business/city-therapeutics-builds-rnai-pipeline-with-99-5m-series-b

    BIOSPACE
    08 Jun 2026
    Share Share
    How To Shine As Biotech Comes Back From The Brink
    How To Shine As Biotech Comes Back From The Brink

    21 May 2026

    // BIOSPACE

    https://www.biospace.com/events/how-to-shine-as-biotech-comes-back-from-the-brink

    BIOSPACE
    21 May 2026
    Share Share
    City Therapeutics Presents RNAi Data for Stargardt at ARVO
    City Therapeutics Presents RNAi Data for Stargardt at ARVO

    06 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260506609437/en/City-Therapeutics-Presents-Preclinical-Data-on-Next-Generation-Investigational-RNAi-Therapy-CITY-RBP4-for-Treatment-of-Stargardt-Disease-at-ARVO-2026-Annual-Meeting

    BUSINESSWIRE
    06 May 2026
    Share Share
    City Therapeutics Files CTA for CITY-FXI RNAi Therapy
    City Therapeutics Files CTA for CITY-FXI RNAi Therapy

    10 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251110671213/en/City-Therapeutics-Announces-Submission-of-Clinical-Trial-Application-for-CITY-FXI-an-Investigational-RNAi-Therapeutic-for-the-Treatment-of-Thromboembolic-Diseases

    BUSINESS WIRE
    10 Nov 2025
    Share Share
    AN Venture Partners Announces Final Close of $200M Fund I
    AN Venture Partners Announces Final Close of $200M Fund I

    02 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250701793878/en/AN-Venture-Partners-Announces-Final-Close-of-%24200M-Fund-I

    BUSINESSWIRE
    02 Jul 2025
    Share Share
    Biogen and City Therapeutics Partner on RNAi-based Therapies
    Biogen and City Therapeutics Partner on RNAi-based Therapies

    27 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/27/3088497/0/en/Biogen-and-City-Therapeutics-Announce-Strategic-Research-Collaboration-to-Develop-Select-Novel-RNAi-based-Therapies.html

    GLOBENEWSWIRE
    27 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search